Role of microRNA deregulation in breast cancer cell chemoresistance and stemness

Current Medicinal Chemistry

Volumn 20, Issue 27, 2013, Pages 3358-3369

  Tekiner, T A ^a   Basaga, H ^a  

^a SABANCI UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Cancer stem cell; Chemoresistance; Mammospheres; microRNA

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 100; MICRORNA 101; MICRORNA 106A; MICRORNA 122; MICRORNA 125B; MICRORNA 126; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 15A; MICRORNA 16; MICRORNA 199A; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 21; MICRORNA 210; MICRORNA 22; MICRORNA 221; MICRORNA 222; MICRORNA 27A; MICRORNA 29; MICRORNA 31; MICRORNA 34A; MICRORNA 375; UNCLASSIFIED DRUG;

ANGIOGENESIS; APOPTOSIS; BIOGENESIS; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DEATH; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CIRCULATING TUMOR CELL; CPG ISLAND; DISTANT METASTASIS; DNA METHYLATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE DOSAGE; GENE EXPRESSION; GENE TARGETING; HISTONE MODIFICATION; INTRON; IONIZING RADIATION; LYMPH NODE METASTASIS; MICROPROCESSOR; ONCOGENE; PHENOTYPE; PROTEIN CLEAVAGE; REVIEW; RNA DEGRADATION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GROWTH; UPREGULATION;

EID: 84883266331     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990003     Document Type: Review

References (100)

1. Zheng, T.; Wang, J.; Chen, X.; Liu, L., Role of microRNA in anticancer drug resistance. Int. J. Cancer, 2010, 126, (1), 2-10.
2. Barbarotto, E.; Schmittgen, T.D.; Calin, G.A., MicroRNAs and cancer: profile, profile, profile. Int. J. Cancer, 2008, 122, (5), 969-977.
3. Ambros, V., The functions of animal microRNAs. Nature, 2004, 431, (7006), 350-355.
4. Vasudevan, S.; Tong, Y.; Steitz, J.A., Switching from repression to activation: microRNAs can up-regulate translation. Science, 2007, 318, (5858), 1931-1934.
5. Molnar, V.; Tamasi, V.; Bakos, B.; Wiener, Z.; Falus, A., Changes in miRNA expression in solid tumors: an miRNA profiling in melanomas. Semin. Cancer Biol., 2008, 18, (2), 111-122.
6. Ferretti, E.; De Smaele, E.; Po, A.; Di Marcotullio, L.; Tosi, E.; Espinola, M.S.; Di Rocco, C.; Riccardi, R.; Giangaspero, F.; Farcomeni, A.; Nofroni, I.; Laneve, P.; Gioia, U.; Caffarelli, E.; Bozzoni, I.; Screpanti, I.; Gulino, A., MicroRNA profiling in human medulloblastoma. Int. J. Cancer, 2009, 124, (3), 568-577.
7. Ichimi, T.; Enokida, H.; Okuno, Y.; Kunimoto, R.; Chiyomaru, T.; Kawamoto, K.; Kawahara, K.; Toki, K.; Kawakami, K.; Nishiyama, K.; Tsujimoto, G.; Nakagawa, M.; Seki, N., Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int. J. Cancer, 2009, 125, (2), 345-352.
8. Akao, Y.; Nakagawa, Y.; Kitade, Y.; Kinoshita, T.; Naoe, T., Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci., 2007, 98, (12), 1914-1920.
9. Chang, S.S.; Jiang, W.W.; Smith, I.; Poeta, L.M.; Begum, S.; Glazer, C.; Shan, S.; Westra, W.; Sidransky, D.; Califano, J.A., MicroRNA alterations in head and neck squamous cell carcinoma. Int. J. Cancer, 2008, 123, (12), 2791-2797.
10. Li, W.; Xie, L.; He, X.; Li, J.; Tu, K.; Wei, L.; Wu, J.; Guo, Y.; Ma, X.; Zhang, P.; Pan, Z.; Hu, X.; Zhao, Y.; Xie, H.; Jiang, G.; Chen, T.; Wang, J.; Zheng, S.; Cheng, J.; Wan, D.; Yang, S.; Li, Y.; Gu, J., Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer, 2008, 123, (7), 1616-1622.
11. Huang, X.A.; Lin, H., The miRNA Regulation of Stem Cells. Wiley interdisciplinary reviews. Membrane transport and signaling, 2012, 1, (1), 83-95.
12. Iorio, M.V.; Croce, C.M., microRNA involvement in human cancer. Carcinogenesis, 2012, 33, (6), 1126-1133.
13. Bhayani, M.K.; Calin, G.A.; Lai, S.Y., Functional relevance of miRNA sequences in human disease. Mutation Res., 2012, 731, (1-2), 14-19.
14. Brennecke, J.; Stark, A.; Russell, R.B.; Cohen, S.M., Principles of microRNA-target recognition. PLoS Biol., 2005, 3, (3), e85.
15. Havens, M.A.; Reich, A.A.; Duelli, D.M.; Hastings, M.L., Biogenesis of mammalian microRNAs by a non-canonical processing pathway. Nucleic Acids Res., 2012, 40, (10), 4626-4640.
16. Bockmeyer, C.L.; Christgen, M.; Muller, M.; Fischer, S.; Ahrens, P.; Langer, F.; Kreipe, H.; Lehmann, U., MicroRNA profiles of healthy basal and luminal mammary epithelial cells are distinct and reflected in different breast cancer subtypes. Breast Cancer Res. Tr., 2011, 130, (3), 735-745.
17. Chin, K.; DeVries, S.; Fridlyand, J.; Spellman, P.T.; Roydasgupta, R.; Kuo, W.L.; Lapuk, A.; Neve, R.M.; Qian, Z.; Ryder, T.; Chen, F.; Feiler, H.; Tokuyasu, T.; Kingsley, C.; Dairkee, S.; Meng, Z.; Chew, K.; Pinkel, D.; Jain, A.; Ljung, B.M.; Esserman, L.; Albertson, D.G.; Waldman, F.M.; Gray, J.W., Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell, 2006, 10, (6), 529-541.
18. Blenkiron, C.; Goldstein, L.D.; Thorne, N.P.; Spiteri, I.; Chin, S.F.; Dunning, M.J.; Barbosa-Morais, N.L.; Teschendorff, A.E.; Green, A.R.; Ellis, I.O.; Tavare, S.; Caldas, C.; Miska, E.A., MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol., 2007, 8, (10), R214.
19. Heneghan, H.M.; Miller, N.; Kerin, M.J., MiRNAs as biomarkers and therapeutic targets in cancer. Current Opin Pharmacol., 2010, 10, (5), 543-550.
20. Mattie, M.D.; Benz, C.C.; Bowers, J.; Sensinger, K.; Wong, L.; Scott, G.K.; Fedele, V.; Ginzinger, D.; Getts, R.; Haqq, C., Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol. Cancer, 2006, 5, 24.
21. Lowery, A.J.; Miller, N.; Devaney, A.; McNeill, R.E.; Davoren, P.A.; Lemetre, C.; Benes, V.; Schmidt, S.; Blake, J.; Ball, G.; Kerin, M.J., MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res., 2009, 11, (3), R27.
22. Zhao, Y.; Srivastava, D., A developmental view of microRNA function. Trends Biochem. Sci., 2007, 32, (4), 189-197.
23. O'Day, E.; Lal, A., MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res., 2010, 12, (2), 201.
24. Lawrie, C.H.; Gal, S.; Dunlop, H.M.; Pushkaran, B.; Liggins, A.P.; Pulford, K.; Banham, A.H.; Pezzella, F.; Boultwood, J.; Wainscoat, J.S.; Hatton, C.S.; Harris, A.L., Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Brit. J. Haematol., 2008, 141, (5), 672-675.
25. Mitchell, P.S.; Parkin, R.K.; Kroh, E.M.; Fritz, B.R.; Wyman, S.K.; Pogosova-Agadjanyan, E.L.; Peterson, A.; Noteboom, J.; O'Briant, K.C.; Allen, A.; Lin, D.W.; Urban, N.; Drescher, C.W.; Knudsen, B.S.; Stirewalt, D.L.; Gentleman, R.; Vessella, R.L.; Nelson, P.S.; Martin, D.B.; Tewari, M., Circulating microRNAs as stable bloodbased markers for cancer detection. Proc. Natl. Acad. Sci. USA, 2008, 105, (30), 10513-10518.
26. Zhu, W.; Qin, W.; Atasoy, U.; Sauter, E.R., Circulating microRNAs in breast cancer and healthy subjects. BMC Res. Notes, 2009, 2, 89.
27. Heneghan, H.M.; Miller, N.; Lowery, A.J.; Sweeney, K.J.; Newell, J.; Kerin, M.J., Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg., 2010, 251, (3), 499-505.
28. Zhao, H.; Shen, J.; Medico, L.; Wang, D.; Ambrosone, C.B.; Liu, S., A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PloS one, 2010, 5, (10), e13735.
29. Roth, C.; Rack, B.; Muller, V.; Janni, W.; Pantel, K.; Schwarzenbach, H., Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res., 2010, 12, (6), R90.
30. Wang, F.; Zheng, Z.; Guo, J.; Ding, X., Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecologic oncology, 2010, 119, (3), 586-593.
31. Asaga, S.; Kuo, C.; Nguyen, T.; Terpenning, M.; Giuliano, A.E.; Hoon, D.S., Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin. Chem., 2011, 57, (1), 84-91.
32. Wu, Q.; Lu, Z.; Li, H.; Lu, J.; Guo, L.; Ge, Q., Next-generation sequencing of microRNAs for breast cancer detection. J. Biomed. Biotechnol., 2011, 2011, 597145.
33. Sieuwerts, A.M.; Mostert, B.; Bolt-de Vries, J.; Peeters, D.; de Jongh, F.E.; Stouthard, J.M.; Dirix, L.Y.; van Dam, P.A.; Van Galen, A.; de Weerd, V.; Kraan, J.; van der Spoel, P.; Ramirez-Moreno, R.; van Deurzen, C.H.; Smid, M.; Yu, J.X.; Jiang, J.; Wang, Y.; Gratama, J.W.; Sleijfer, S.; Foekens, J.A.; Martens, J.W., mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clin. Cancer Res., 2011, 17, (11), 3600-3618.
34. Schrauder, M.G.; Strick, R.; Schulz-Wendtland, R.; Strissel, P.L.; Kahmann, L.; Loehberg, C.R.; Lux, M.P.; Jud, S.M.; Hartmann, A.; Hein, A.; Bayer, C.M.; Bani, M.R.; Richter, S.; Adamietz, B.R.; Wenkel, E.; Rauh, C.; Beckmann, M.W.; Fasching, P.A., Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PloS one, 2012, 7, (1), e29770.
35. Wu, X.; Somlo, G.; Yu, Y.; Palomares, M.R.; Li, A.X.; Zhou, W.; Chow, A.; Yen, Y.; Rossi, J.J.; Gao, H.; Wang, J.; Yuan, Y.C.; Frankel, P.; Li, S.; Ashing-Giwa, K.T.; Sun, G.; Wang, Y.; Smith, R.; Robinson, K.; Ren, X.; Wang, S.E., De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J. Transl. Med., 2012, 10, 42.
36. Cuk, K.; Zucknick, M.; Heil, J.; Madhavan, D.; Schott, S.; Turchinovich, A.; Arlt, D.; Rath, M.; Sohn, C.; Benner, A.; Junkermann, H.; Schneeweiss, A.; Burwinkel, B., Circulating microRNAs in plasma as early detection markers for breast cancer. Int. J. Cancer, 2012.
37. Iwasa, Y.; Nowak, M.A.; Michor, F., Evolution of resistance during clonal expansion. Genetics, 2006, 172, (4), 2557-2566.
38. Egger, G.; Liang, G.; Aparicio, A.; Jones, P.A., Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004, 429, (6990), 457-463.
39. Kutanzi, K.R.; Yurchenko, O.V.; Beland, F.A.; Checkhun, V.F.; Pogribny, I.P., MicroRNA-mediated drug resistance in breast cancer. Clin. Epigenetics, 2011, 2, (2), 171-185.
40. Deng, S.; Calin, G.A.; Croce, C.M.; Coukos, G.; Zhang, L., Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 2008, 7, (17), 2643-2646.
41. Croce, C.M., Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genetics, 2009, 10, (10), 704-714.
42. Kalluri, R.; Weinberg, R.A., The basics of epithelial-mesenchymal transition. J. Clin. Invest., 2009, 119, (6), 1420-1428.
43. Medema, J.P., Cancer stem cells: The challenges ahead. Nat. Cell. Biol., 2013, 15, (4), 338-344.
44. Wellner, U.; Schubert, J.; Burk, U.C.; Schmalhofer, O.; Zhu, F.; Sonntag, A.; Waldvogel, B.; Vannier, C.; Darling, D.; zur Hausen, A.; Brunton, V.G.; Morton, J.; Sansom, O.; Schuler, J.; Stemmler, M.P.; Herzberger, C.; Hopt, U.; Keck, T.; Brabletz, S.; Brabletz, T., The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell. Biol., 2009, 11, (12), 1487-1495.
45. Li, X.J.; Ji, M.H.; Zhong, S.L.; Zha, Q.B.; Xu, J.J.; Zhao, J.H.; Tang, J.H., MicroRNA-34a modulates chemosensitivity of breast cancer cells to adriamycin by targeting Notch1. Arch. Med. Res., 2012, 43, (7), 514-521.
46. Wang, H.; Tan, G.; Dong, L.; Cheng, L.; Li, K.; Wang, Z.; Luo, H., Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS one, 2012, 7, (4), e34210.
47. Jung, E.J.; Santarpia, L.; Kim, J.; Esteva, F.J.; Moretti, E.; Buzdar, A.U.; Di Leo, A.; Le, X.F.; Bast, R.C., Jr.; Park, S.T.; Pusztai, L.; Calin, G.A., Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 2012, 118, (10), 2603-2614.
48. Kovalchuk, O.; Filkowski, J.; Meservy, J.; Ilnytskyy, Y.; Tryndyak, V.P.; Chekhun, V.F.; Pogribny, I.P., Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol. Cancer Ther., 2008, 7, (7), 2152-2159.
49. Bu, Y.; Lu, C.; Bian, C.; Wang, J.; Li, J.; Zhang, B.; Li, Z.; Brewer, G.; Zhao, R.C., Knockdown of Dicer in MCF-7 human breast carcinoma cells results in G1 arrest and increased sensitivity to cisplatin. Oncology Rep., 2009, 21, (1), 13-17.
50. Rhodes, L.V.; Nitschke, A.M.; Segar, H.C.; Martin, E.C.; Driver, J.L.; Elliott, S.; Nam, S.Y.; Li, M.; Nephew, K.P.; Burow, M.E.; Collins-Burow, B.M., The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncology Rep., 2012, 27, (1), 10-16.
51. Zhao, Y.; Deng, C.; Lu, W.; Xiao, J.; Ma, D.; Guo, M.; Recker, R.R.; Gatalica, Z.; Wang, Z.; Xiao, G.G., let-7 microRNAs induce tamoxifen sensitivity by downregulation of estrogen receptor alpha signaling in breast cancer. Mol. Med., 2011, 17, (11-12), 1233-1241.
52. Pogribny, I.P.; Filkowski, J.N.; Tryndyak, V.P.; Golubov, A.; Shpyleva, S.I.; Kovalchuk, O., Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int. J. Cancer, 2010, 127, (8), 1785-1794.
53. Zhou, M.; Liu, Z.; Zhao, Y.; Ding, Y.; Liu, H.; Xi, Y.; Xiong, W.; Li, G.; Lu, J.; Fodstad, O.; Riker, A.I.; Tan, M., MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J. Biol. Chem., 2010, 285, (28), 21496-21507.
54. Cittelly, D.M.; Das, P.M.; Salvo, V.A.; Fonseca, J.P.; Burow, M.E.; Jones, F.E., Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 2010, 31, (12), 2049-2057.
55. Kastl, L.; Brown, I.; Schofield, A.C., miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res.Tr., 2012, 131, (2), 445-454.
56. Liang, Z.; Li, Y.; Huang, K.; Wagar, N.; Shim, H., Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm. Res., 2011, 28, (12), 3091-3100.
57. Yu, Y.; Wang, Y.; Ren, X.; Tsuyada, A.; Li, A.; Liu, L.J.; Wang, S.E., Context-dependent bidirectional regulation of the MutS homolog 2 by transforming growth factor beta contributes to chemoresistance in breast cancer cells. Mol. Cancer Res., 2010, 8, (12), 1633-1642.
58. Gong, C.; Yao, Y.; Wang, Y.; Liu, B.; Wu, W.; Chen, J.; Su, F.; Yao, H.; Song, E., Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J. Biol. Chem., 2011, 286, (21), 19127-19137.
59. Bourguignon, L.Y.; Spevak, C.C.; Wong, G.; Xia, W.; Gilad, E., Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem., 2009, 284, (39), 26533-26546.
60. Liang, Z.; Wu, H.; Xia, J.; Li, Y.; Zhang, Y.; Huang, K.; Wagar, N.; Yoon, Y.; Cho, H.T.; Scala, S.; Shim, H., Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol., 2010, 79, (6), 817-824.
61. Lobert, S.; Jefferson, B.; Morris, K., Regulation of beta-tubulin isotypes by micro-RNA 100 in MCF7 breast cancer cells. Cytoskeleton, 2011, 68, (6), 355-362.
62. Sachdeva, M.; Wu, H.; Ru, P.; Hwang, L.; Trieu, V.; Mo, Y.Y., MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene, 2011, 30, (7), 822-831.
63. Masri, S.; Phung, S.; Wang, X.; Chen, S., Molecular characterization of aromatase inhibitor-resistant, tamoxifenresistant and LTEDaro cell lines. J. Steroid Biochem. Mol. Biol., 2010, 118, (4-5), 277-282.
64. Kong, W.; He, L.; Coppola, M.; Guo, J.; Esposito, N.N.; Coppola, D.; Cheng, J.Q., MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem., 2010, 285, (23), 17869-17879.
65. Shatseva, T.; Lee, D.Y.; Deng, Z.; Yang, B.B., MicroRNA miR-199a-3p regulates cell proliferation and survival by targeting caveolin-2. J. Cell Sci., 2011, 124, (Pt 16), 2826-2836.
66. Kopp, F.; Oak, P.S.; Wagner, E.; Roidl, A., miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PloS one, 2012, 7, (11), e50469.
67. Ru, P.; Steele, R.; Hsueh, E.C.; Ray, R.B., Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes & Cancer, 2011, 2, (7), 720-727.
68. Iorio, M.V.; Casalini, P.; Piovan, C.; Di Leva, G.; Merlo, A.; Triulzi, T.; Menard, S.; Croce, C.M.; Tagliabue, E., microRNA-205 regulates HER3 in human breast cancer. Cancer Res., 2009, 69, (6), 2195-2200.
69. Miller, T.E.; Ghoshal, K.; Ramaswamy, B.; Roy, S.; Datta, J.; Shapiro, C.L.; Jacob, S.; Majumder, S., MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J. Biol. Chem., 2008, 283, (44), 29897-29903.
70. Zhao, J.J.; Lin, J.; Yang, H.; Kong, W.; He, L.; Ma, X.; Coppola, D.; Cheng, J.Q., MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J. Biol. Chem., 2008, 283, (45), 31079-31086.
71. Rao, X.; Di Leva, G.; Li, M.; Fang, F.; Devlin, C.; Hartman-Frey, C.; Burow, M.E.; Ivan, M.; Croce, C.M.; Nephew, K.P., MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene, 2011, 30, (9), 1082-1097.
72. Bao, L.; Hazari, S.; Mehra, S.; Kaushal, D.; Moroz, K.; Dash, S., Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am. J. Pathol., 2012, 180, (6), 2490-2503.
73. Shi, W.; Gerster, K.; Alajez, N.M.; Tsang, J.; Waldron, L.; Pintilie, M.; Hui, A.B.; Sykes, J.; P'ng, C.; Miller, N.; McCready, D.; Fyles, A.; Liu, F.F., MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res., 2011, 71, (8), 2926-2937.
74. Pan, Y.Z.; Morris, M.E.; Yu, A.M., MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol., 2009, 75, (6), 1374-1379.
75. Cittelly, D.M.; Das, P.M.; Spoelstra, N.S.; Edgerton, S.M.; Richer, J.K.; Thor, A.D.; Jones, F.E., Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol. Cancer, 2010, 9, 317.
76. Shah, M.Y.; Pan, X.; Fix, L.N.; Farwell, M.A.; Zhang, B., 5-Fluorouracil drug alters the microRNA expression profiles in MCF-7 breast cancer cells. J. Cell. Physiol., 2011, 226, (7), 1868-1878.
77. Ward, A.; Balwierz, A.; Zhang, J.D.; Kublbeck, M.; Pawitan, Y.; Hielscher, T.; Wiemann, S.; Sahin, O., Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene, 2012.
78. Bergamaschi, A.; Katzenellenbogen, B.S., Tamoxifen downregulation of miR-451 increases 14-3-3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene, 2012, 31, (1), 39-47.
79. Yamamoto, Y.; Yoshioka, Y.; Minoura, K.; Takahashi, R.U.; Takeshita, F.; Taya, T.; Horii, R.; Fukuoka, Y.; Kato, T.; Kosaka, N.; Ochiya, T., An integrative genomic analysis revealed the relevance of microRNA and gene expression for drug-resistance in human breast cancer cells. Mol. Cancer, 2011, 10, 135.
80. Dick, J.E., Stem cell concepts renew cancer research. Blood, 2008, 112, (13), 4793-4807.
81. Dean, M.; Fojo, T.; Bates, S., Tumour stem cells and drug resistance. Nat. Rev. Cancer, 2005, 5, (4), 275-284.
82. Kitamura, H.; Okudela, K.; Yazawa, T.; Sato, H.; Shimoyamada, H., Cancer stem cell: implications in cancer biology and therapy with special reference to lung cancer. Lung Cancer, 2009, 66, (3), 275-281.
83. Al-Hajj, M.; Wicha, M.S.; Benito-Hernandez, A.; Morrison, S.J.; Clarke, M.F., Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA, 2003, 100, (7), 3983-3988.
84. Wright, M.H.; Calcagno, A.M.; Salcido, C.D.; Carlson, M.D.; Ambudkar, S.V.; Varticovski, L., Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. Breast Cancer Res., 2008, 10, (1), R10.
85. Hwang-Verslues, W.W.; Kuo, W.H.; Chang, P.H.; Pan, C.C.; Wang, H.H.; Tsai, S.T.; Jeng, Y.M.; Shew, J.Y.; Kung, J.T.; Chen, C.H.; Lee, E.Y.; Chang, K.J.; Lee, W.H., Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PloS One, 2009, 4, (12), e8377.
86. Ginestier, C.; Hur, M.H.; Charafe-Jauffret, E.; Monville, F.; Dutcher, J.; Brown, M.; Jacquemier, J.; Viens, P.; Kleer, C.G.; Liu, S.; Schott, A.; Hayes, D.; Birnbaum, D.; Wicha, M.S.; Dontu, G., ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell, 2007, 1, (5), 555-567.
87. Pece, S.; Tosoni, D.; Confalonieri, S.; Mazzarol, G.; Vecchi, M.; Ronzoni, S.; Bernard, L.; Viale, G.; Pelicci, P.G.; Di Fiore, P.P., Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell, 2010, 140, (1), 62-73.
88. Signore, M.; Ricci-Vitiani, L.; De Maria, R., Targeting apoptosis pathways in cancer stem cells. Cancer Lett., 2011.
89. Loebinger, M.R.; Giangreco, A.; Groot, K.R.; Prichard, L.; Allen, K.; Simpson, C.; Bazley, L.; Navani, N.; Tibrewal, S.; Davies, D.; Janes, S.M., Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Brit. J. Cancer, 2008, 98, (2), 380-387.
90. Zhu, Y.; Yu, F.; Jiao, Y.; Feng, J.; Tang, W.; Yao, H.; Gong, C.; Chen, J.; Su, F.; Zhang, Y.; Song, E., Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5. Clin. Cancer Res., 2011, 17, (22), 7105-7115.
91. Li, X.; Pan, Y.Z.; Seigel, G.M.; Hu, Z.H.; Huang, M.; Yu, A.M., Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem. Pharmacol., 2011, 81, (6), 783-792.
92. Bourguignon, L.Y., Hyaluronan-mediated CD44 activation of RhoGTPase signaling and cytoskeleton function promotes tumor progression. Semin. Cancer Biol., 2008, 18, (4), 251-259.
93. Fletcher, J.I.; Haber, M.; Henderson, M.J.; Norris, M.D., ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer, 2010, 10, (2), 147-156.
94. Yu, F.; Yao, H.; Zhu, P.; Zhang, X.; Pan, Q.; Gong, C.; Huang, Y.; Hu, X.; Su, F.; Lieberman, J.; Song, E., let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell, 2007, 131, (6), 1109-1123.
95. Oliveras-Ferraros, C.; Cufi, S.; Vazquez-Martin, A.; Torres-Garcia, V.Z.; Del Barco, S.; Martin-Castillo, B.; Menendez, J.A., Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: induction of the tumor suppressor miRNA let-7a and suppression of the TGFbetainduced oncomiR miRNA-181a. Cell Cycle, 2011, 10, (7), 1144-1151.
96. Wang, Y.; Yu, Y.; Tsuyada, A.; Ren, X.; Wu, X.; Stubblefield, K.; Rankin-Gee, E.K.; Wang, S.E., Transforming growth factor-beta regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene, 2011, 30, (12), 1470-1480.
97. Hwang-Verslues, W.W.; Chang, P.H.; Wei, P.C.; Yang, C.Y.; Huang, C.K.; Kuo, W.H.; Shew, J.Y.; Chang, K.J.; Lee, E.Y.; Lee, W.H., miR-495 is upregulated by E12/E47 in breast cancer stem cells, and promotes oncogenesis and hypoxia resistance via downregulation of E-cadherin and REDD1. Oncogene, 2011, 30, (21), 2463-2474.
98. Sun, J.G.; Liao, R.X.; Qiu, J.; Jin, J.Y.; Wang, X.X.; Duan, Y.Z.; Chen, F.L.; Hao, P.; Xie, Q.C.; Wang, Z.X.; Li, D.Z.; Chen, Z.T.; Zhang, S.X., Microarray-based analysis of microRNA expression in breast cancer stem cells. J. Exp. Clin. Canc. Res., 2010, 29, 174.
99. Shimono, Y.; Zabala, M.; Cho, R.W.; Lobo, N.; Dalerba, P.; Qian, D.; Diehn, M.; Liu, H.; Panula, S.P.; Chiao, E.; Dirbas, F.M.; Somlo, G.; Pera, R.A.; Lao, K.; Clarke, M.F., Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell, 2009, 138, (3), 592-603.
100. Brabletz, S.; Bajdak, K.; Meidhof, S.; Burk, U.; Niedermann, G.; Firat, E.; Wellner, U.; Dimmler, A.; Faller, G.; Schubert, J.; Brabletz, T., The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J., 2011, 30, (4), 770-782.